{"id":153471,"date":"2026-11-16T11:46:53","date_gmt":"2026-11-16T02:46:53","guid":{"rendered":"https:\/\/japanir.jp\/en\/ir\/3750-20261116-01_wp_sales_update\/"},"modified":"2026-11-16T11:46:53","modified_gmt":"2026-11-16T02:46:53","slug":"3750-20261116-01_wp_sales_update","status":"publish","type":"ir_release","link":"https:\/\/japanir.jp\/en\/company\/company-3750\/ir\/3750-20261116-01_wp_sales_update\/","title":{"rendered":"Notice of New Orders for High-Concentration Exosome Component Solution &#8220;NeoCella&#8221; Related Products"},"content":{"rendered":"<p>ADR Therapeutics, a consolidated subsidiary, secured a new order for NeoCella-related products. Total orders amount to 11,000 sets, with delivery scheduled for 2026-11-16. Sales are expected to correspond to 20% of the prior fiscal year\u2019s net sales and will be recorded in Q3 of the fiscal year ending March 2027. The impact is currently under review.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"3750","jir_company_name":"ADR Biomedical Holdings Inc.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-11-16","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/3750-20261116-01.pdf","jir_short_summary":"ADR Therapeutics, a consolidated subsidiary, secured a new order for NeoCella-related products. Total orders amount to 11,000 sets, with delivery scheduled for 2026-11-16. Sales are expected to correspond to 20% of the prior fiscal year\u2019s net sales and will be recorded in Q3 of the fiscal year ending March 2027. The impact is currently under review.","jir_summary":"### Business Developments\nADR Therapeutics (a consolidated subsidiary) is advancing R&D and sales structures for the high-concentration exosome component solution \"NeoCella\" and has received a contract to supply 11,000 sets to a general incorporated association as a new provision project. Delivery is scheduled for 2026-11-16, and the revenue scale is expected to be equivalent to 20% of the immediately preceding fiscal year\u2019s net sales. Revenue will be recognized upon completion of product delivery and is expected to be recorded in Q3 of the fiscal year ending March 2027.\n\n### Financial Impact\nThe impact of this order on consolidated results is currently under review, and any matters that should be disclosed will be announced promptly. Although the order size may be material relative to annual net sales, specific figures and segmental impacts remain unknown.","jir_financial_highlights":"NeoCella-related product order quantity: 11,000 sets (Unknown)\nEstimated sales contribution: Equivalent to 20% of prior fiscal year net sales (Unknown)\nScheduled delivery date: 2026-11-16 (Unknown)\nTiming of revenue recognition: Q3 of fiscal year ending March 2027 (Unknown)","jir_category":"","jir_hashtags":"#ADRBiomedicalHoldings, #NeoCella, #OrderReceived, #MedicalProducts","jir_key_figures":"11,000 sets\n20% (equivalent to prior fiscal year net sales)\n2026-11-16","jir_meta_title":"ADR Biomedical Holdings Inc. Announces New NeoCella Order\uff5cNovember 2026","jir_meta_description":"ADR group announces a new order for NeoCella-related products totaling 11,000 sets. Delivery is scheduled for 2026-11-16 and revenue recognition is expected in Q3 of the fiscal year ending March 2027. Estimated sales contribution equals 20% of prior fiscal year net sales.","jir_og_title":"ADR Biomedical Holdings Inc. Announces New NeoCella Order\uff5cNovember 2026","jir_og_description":"Secured a new order of 11,000 sets for NeoCella-related products. Delivery on 2026-11-16 and revenue recognition expected in Q3 of the fiscal year ending March 2027.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":59367,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"sales_update","footnotes":""},"sector":[],"importance":[],"class_list":["post-153471","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Notice of New Orders for High-Concentration Exosome Component Solution &quot;NeoCella&quot; Related Products - Japan IR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/japanir.jp\/en\/company\/company-3750\/ir\/3750-20261116-01_wp_sales_update\/\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-3750\/ir\/3750-20261116-01_wp_sales_update\/\",\"url\":\"https:\/\/japanir.jp\/en\/company\/company-3750\/ir\/3750-20261116-01_wp_sales_update\/\",\"name\":\"Notice of New Orders for High-Concentration Exosome Component Solution \\\"NeoCella\\\" Related Products - Japan IR\",\"isPartOf\":{\"@id\":\"https:\/\/japanir.jp\/en\/#website\"},\"datePublished\":\"2026-11-16T02:46:53+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-3750\/ir\/3750-20261116-01_wp_sales_update\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/japanir.jp\/en\/company\/company-3750\/ir\/3750-20261116-01_wp_sales_update\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-3750\/ir\/3750-20261116-01_wp_sales_update\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/japanir.jp\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Notice of New Orders for High-Concentration Exosome Component Solution &#8220;NeoCella&#8221; Related Products\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/japanir.jp\/en\/#website\",\"url\":\"https:\/\/japanir.jp\/en\/\",\"name\":\"Japan IR\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/japanir.jp\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Notice of New Orders for High-Concentration Exosome Component Solution \"NeoCella\" Related Products - Japan IR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/japanir.jp\/en\/company\/company-3750\/ir\/3750-20261116-01_wp_sales_update\/","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/japanir.jp\/en\/company\/company-3750\/ir\/3750-20261116-01_wp_sales_update\/","url":"https:\/\/japanir.jp\/en\/company\/company-3750\/ir\/3750-20261116-01_wp_sales_update\/","name":"Notice of New Orders for High-Concentration Exosome Component Solution \"NeoCella\" Related Products - Japan IR","isPartOf":{"@id":"https:\/\/japanir.jp\/en\/#website"},"datePublished":"2026-11-16T02:46:53+00:00","breadcrumb":{"@id":"https:\/\/japanir.jp\/en\/company\/company-3750\/ir\/3750-20261116-01_wp_sales_update\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/japanir.jp\/en\/company\/company-3750\/ir\/3750-20261116-01_wp_sales_update\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/japanir.jp\/en\/company\/company-3750\/ir\/3750-20261116-01_wp_sales_update\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/japanir.jp\/en\/"},{"@type":"ListItem","position":2,"name":"Notice of New Orders for High-Concentration Exosome Component Solution &#8220;NeoCella&#8221; Related Products"}]},{"@type":"WebSite","@id":"https:\/\/japanir.jp\/en\/#website","url":"https:\/\/japanir.jp\/en\/","name":"Japan IR","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/japanir.jp\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"related_company_data":{"id":"59367","title":"ADR120S INC","ticker":"3750"},"_links":{"self":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release\/153471","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release"}],"about":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/types\/ir_release"}],"replies":[{"embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/comments?post=153471"}],"version-history":[{"count":0,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release\/153471\/revisions"}],"wp:attachment":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/media?parent=153471"}],"wp:term":[{"taxonomy":"sector","embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/sector?post=153471"},{"taxonomy":"importance","embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/importance?post=153471"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}